Biologics protect psoriasis patients from being exacerbated by COVID-19 infection.

Publication date: Jan 30, 2024

Patients with psoriasis may experience an exacerbation in symptoms following COVID-19 infection. After abandoning ‘zero COVID’ strategies, China experienced a surge of Omicron infections. We aimed to investigate psoriasis exacerbation in psoriatic patients with COVID-19, following treatment with three different biologics, adalimumab, secukinumab, and ixekizumab. We performed a prospective study (n = 209) at our hospital between November 01, 2022, and February 15, 2023. We defined △ PASI as post-COVID-19 PASI minus pre-COVID-19 PASI. Two endpoints were set in this study. △ PASI >0 was defined as exacerbation of psoriasis after infection. △ PASI >3 was defined as a severe exacerbation of psoriasis symptoms after infection. In addition, serum OAS1, OAS2, and OAS3 were also assessed. Results showed that the severity of psoriasis can worsen after COVID-19 infection, and a smaller proportion of patients taking biologics developed worsening psoriasis compared to those not using biologics; however, only the patients taking ixekizumab demonstrated a statistically significant difference (p

Concepts Keywords
Biologics Biologics
China COVID-19
February OAS
Infections Psoriasis

Semantics

Type Source Name
disease MESH psoriasis
disease MESH COVID-19
disease MESH infection
drug DRUGBANK Adalimumab
drug DRUGBANK Secukinumab
drug DRUGBANK Ixekizumab

Original Article

(Visited 2 times, 1 visits today)